medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 05

<< Back

Ginecol Obstet Mex 2021; 89 (05)

Laryngeal papillomatosis as a cause of maternal death

Jiménez-Herrera R, Fernández-Vázquez MU, Quiterio-Montiel EC, Hernández y Ballinas A, Palmer-Márquez ML

Language: Spanish
References: 27
Page: 424-429
PDF size: 246.29 Kb.


ABSTRACT

Background: The WHO reports that the main complications that cause 75% of maternal deaths are: severe hemorrhage, infections, gestational hypertension, complications in childbirth and others. Most of these complications can be prevented and treated. Laryngeal papillomatosis is a heterogeneous, rare and chronic disease. In rare cases it can have an aggressive course, with damage to the fetus and respiratory tract.
Clinical case: A 34-year-old patient, 32 weeks pregnant, died at home due to asphyxia after receiving first aid. The medico-legal autopsy reported the existence of an endolaryngeal tumor, with a forensic histopathological diagnosis of laryngeal papillomatosis. Real-time PCR for HPV detection and genotyping was performed on a kerosene block, which reported co-infection by two different virus genotypes: 18 and 6.
Conclusions: Laryngeal papillomatosis is a rare disease. Pregnancy is a factor that favors the appearance of papillomatous lesions due to decreased immune response. Ignorance of the disease does not exempt the responsibility of a maternal death that could have been avoided with an adequate diagnosis and treatment.


REFERENCES

  1. Alkema L, Chou D, Hogan D, Zhang S, Moller A, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: A systematic analysis by the UN maternal mortality estimation inter-agency group. Lancet 2016; 387 (10017): 462-74. doi:10.1016/S0140-6736(15)00838-7.

  2. Say L, Chou D, Gemmill A, Tunçalp O, Moller A, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet 2014; 2 (6): 323-33. doi.org/10.1016/ S2214-109x(14)70227-X.

  3. Patton G, Coffey C, Sawyer S, Viner R, Haller D, Bose K, et al. Global causes of maternal death: a WHO systematic analysis. Lancet 2009; 374 (9693): 881-92. doi.org/10.1016/ S0140-6736(09)60741-8.

  4. Halperin I, Obiols G, Soto Moreno A, Torres-Vela E, Henzi T, Bauset M, et al. Clinical practice guideline for hypotalamicpituitary disturbances in pregnancy and the postpartum period. Endocrinol Nutr 2008; 55 (1): 29-43. doi:10.1016/ S1575-0922(08)70633-8.

  5. Ramos-e-Silva M, Martins NR, Kroumpouzos G. Oral and genital changes in pregnancy. Clinics in Dermatology 2016; 34 (3): 353-58. doi:10.1016/j.clindermatol.2016.02.007.

  6. Riviero H, Mussivon F, Luiz D, Araujo CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: A state-of-the-art review. Respiratory Medicine, 2017; 126: 116-21. doi:10.1016/j.rmed.2017.03.030.

  7. Sonawade K, Suk R, Chiao E Y, Chhatwal J, Qiu P, Wilkin T, et al. Oral human papillomavirus infection: differences in prevalence between sexes and concordance with genital human papillomavirus infection, NHANES 2011 to 2014. Ann Intern Med 2019; 167 (10): 714-24. doi. org/10.7326/M17-1363

  8. Ivancic R, Iqbal H, deSilva B, Pan Q, Matrka L. Immunological tolerance of low‐risk HPV in recurrent respiratory papillomatosis. Clin Experimen Immunol 2019; 199 (2): 131-142. doi:10.1111/cei.13387.

  9. Hu L, Benedict PA, Garber D, Wang B, Amin MR, Branski RC. Laryngeal distribution of adult‐onset recurrent respiratory papillomatosis: A longitudinal study. Laryngoscope 2019; 129 (9): 1993-97. doi:10.1002/lary.27694.

  10. Formánek M, Jančatová D, Komínek P, Matoušek P, Zeleník K. Laryngopharyngeal reflux and herpes simplex virus type 2 are possible risk factors for adult‐onset recurrent respiratory papillomatosis (prospective case–control study). Clinical Otolaryngology 2017; 42 (3) :597-601. doi:10.1111/ coa.12779.

  11. Centurión AM, Coria MB, Chaparro AM, De Barros Barreto AC, Destéfano AT, Martínez C. Características clínicas de casos diagnosticados con papilomatosis laríngea en el servicio de Otorrinolaringología del Hospital de Clínicas, San Lorenzo-Paraguay (2010-2015). Discover Medicine 2018; 2 (1): 33-8.

  12. Tinoco K, Juárez M. Características clínicas y epidemiológicas de la papilomatosis respiratoria recurrente en pacientes pediátricos del Servicio Desconcentrado Hospital Pediatrico Agustin Zubillaga. Boletín Médico de Postgrado 2019; 35 (2): 49-50.

  13. Derkay CS, Bluher AE. Update on recurrent respiratory papillomatosis. Otol Clin North Am 2019; 52 (4): 669-79. https//doi.org/10.1016/j.otc.2019.03.011.

  14. Romero-Arias T, Hernandez-Kauffman C, Arias-Hernández M, Ramos-Rodríguez P, Serdio-Arias JL. Papilomatosis laríngea recurrente en la patología vocal: a propósito de un caso. Majorensis: Revista Electrónica de Ciencia y Tecnología 2016 (12): 56-61.

  15. Barrera D, Arnold ML, Peña CL, Alfonso J. Papilomatosis laríngea recurrente con seguimiento multidisciplinario. A propósito de un caso. Rev Med Electrón 2016; 38(4): 595-601. http://scielo.sld.cu/scielo.php?script=sci_ arttext&pid=S1684-18242016000400009&lng=es.

  16. Alarcón L, Arias J, Arce C, Lee C, Torres A, Yoffe I, et al. Papilomatosis laríngea recurrente contransformación a carcinoma pulmonar Cir Parag 2013; 37 (1): 27-30.

  17. Pachar-Lucio JV, Rodríguez-Pachar G, Barraza-Langshaw M. y Trejos-Justiniani, D. Asfixia por papilomatosis respiratoria recurrente. Revista Española de Medicina Legal 2016; 42 (1): 37-40. doi:10.1016/j.reml.2015.07.002.

  18. Cuestas G, Rodríguez V, Doormann F, Bellia P. y Bellia, G. Papilomatosis laríngea: una causa poco frecuente de disfonía en el niño. Serie de casos. Arch Argent Pediatr 2018; 116 (3): 471-75. doi.10.5546/aap.2018.e471.

  19. Perrone M, Pinchak C, Akiki A, Moreira I, Amaro V, Pujadas M, et al. Papilomatosis respiratoria: un reto diagnóstico y terapéutico. A propósito de un caso. Archivos de Pediatría del Uruguay, 2020; 91 (3): 155-60. http://dx.doi. org/10.31134/ap.91.3.5.

  20. Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz L, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years -United States, 2016. MMWR 2017; 66 (33): 874-82. doi:10.15585/mmwr.mm6633a2.

  21. Novakovic D, Cheng A, Zurynski Y, Booy R, Walker R, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infectious Dis 2018; 217 (2): 208-12. https://doi. org/10.1093/infdis/jix498

  22. Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. Jama 2016; 316 (22): 2411-21. doi:10.1001/jama.2016.17615.

  23. Bailon E, Ortega A, Prieto L. Intervenciones preventivas en el embarazo. Formación Médica Continuada en Atención Primaria 2015; 22 (5): 258-63. doi:10.1016/j. fmc.2015.01.004.

  24. OMS. Estrategia Mundial para la Salud de la Mujer, el Niño y el Adolescente ( 2016-2030) : informe del Director General (No. A72/30). 2019 Organización Mundial de la Salud. www.apps.who.int.

  25. Souza J. A mortalidade materna e os novos objetivos de desenvolvimento sustentável (2016-2030). Revista Brasileira de Ginecologia e Obstetrícia, 2015; 37 (12): 549-51. doi.org/10.1590/SO100-720320150005526.

  26. Ruiz MT, Miller T, Márquez L, Villarroel MC. Hacia la armonización de las estimaciones de mortalidad materna en América Latina: actualización y ampliación a los 20 países de la región. Cepal, noviembre 2015.

  27. Organización Mundial de la Salud. Tendencias de la mortalidad materna: 1990 a 2013: estimaciones de la OMS, UNICEF, UNFPA, el Banco Mundial y la División de Población de las Naciones Unidas. 2014. http://apps.who.int/iris/ bitstream/10665/112682/2/ 9789241507226_eng.pdf.




2020     |     www.medigraphic.com